Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-008618
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-08 20:43:18
Reporting Period:
2018-02-06
Accepted Time:
2018-02-08 20:43:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1339970 Atyr Pharma Inc LIFE Biological Products, (No Disgnostic Substances) (2836) 203435077
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657162 T John Blake 3545 John Hopkins Court, Suite 250
San Diego CA 92121
Senior Vice President, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-07 3,334 $0.00 3,334 No 4 M Direct
Common Stock Disposition 2018-02-08 1,402 $3.40 1,932 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2018-02-06 75,000 $0.00 75,000 $3.30
Common Stock Restricted Stock Units Disposition 2018-02-07 3,334 $0.00 3,334 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,000 2028-02-06 No 4 A Direct
6,666 No 4 M Direct
Footnotes
  1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017.
  2. Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017.
  3. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
  4. The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018.